SMC recommends Bayer’s cancer treatments for NHS Scotland use
Eligible patients in Scotland will now have access to Nubeqa and Stivarga
Read More
Tag: regorafenib
Blueprint’s Ayvakit fails to best Bayer’s Stivarga
The firm said based on the data it would not be pursuing further development of the drug in GIST beyond its approved indication
Read More
Bayer’s Stivarga wins NICE backing for advanced liver cancer
Bayer’s Stivarga has been recommended for use on the NHS by the National Institute for Health and Care Excellence (NICE) following a rapid review of guidance published earlier in the year.
Read More
Roche’s Tecentriq/Cotellic study fails in colorectal cancer trial
Roche has revealed that a combination of Tecentriq and Cotellic tested in a late-stage trial failed to improve overall survival compared to regorafenib in patients with advanced metastatic colorectal cancer (CRC).
Read More
Five therapies endorsed for use on NHS Scotland
A new treatment option for the very rare condition infantile onset 5q spinal muscular atrophy (type I SMA) is among five medicines that have been endorsed by Scottish cost regulators for use on the NHS.
Read More
Liver cancer patients barred from NHS access to Bayer’s Stivarga
It is now looking very unlikely that patients with liver cancer will get access to Bayer’s Stivarga on the NHS, after cost regulators issued final draft guidelines rejecting funding for the drug in this setting.
Read More
Bayer’s Stivarga wins NICE approval for GIST
Bayer’s Stivarga has been recommended by the National Institute for Health and Care Excellence as a treatment for some patients with gastrointestinal stromal tumours (GIST).
Read More
NICE turns down Bayer’s Stivarga for liver cancer
Bayer’s Stivarga is not being recommended by NHS treatment cost regulators for certain patients with advanced unresectable hepatocellular carcinoma.
Read More
NICE backing for Bayer’s Stivarga in GIST
Bayer’s Stivarga is being backed by the National Institute for Health and Care Excellence as a cost-effective option for the treatment of adults with gastrointestinal stromal tumours (GIST).
Read More
Priority review in the US for Bayer’s liver cancer drug
US regulators will undertake a speedy review of Bayer’s application to expand the reach of its cancer drug regorafenib to include the second-line treatment of patients with unresectable hepatocellular carcinoma (uHCC).
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
